-
Drugs
Emergency Preparedness
Bioterrorism, drug preparedness and natural disaster response
Drug Approvals and DatabasesDrug-Related Databases from FDA; Information on Drug Approvals
Drug Safety and AvailabilityMedication Guides, Drug Shortages, Public Health Advisories and Other Safety Announcements
Development & Approval Process (Drugs)Conducting Clinical Trials, Types of Drug Applications, Forms and Submissions Requirements
Guidance, Compliance & Regulatory Information
Guidance for Industry, Warning Letters, Postmarket Surveillance Programs
News & EventsWhat's New on This Site, Drug Approval Listing, Meetings and Conferences
Science & Research (Drugs)Research by FDA Staff to Evaluate and Enhance the Safety of Drug Products
Resources for YouFor Consumers, Health Professionals, Industry
-
News and Announcements
- FDA Takes Actions on Darvon, Other Pain Medications Containing Propoxyphene
- Information for Healthcare Professionals: Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics)
- Public Health Advisory: FDA Requires New Boxed Warnings for the Smoking Cessation Drugs Chantix and Zyban
-
-
Drug Safety
-
-
-
Spotlight
-
-
Recalls & Alerts
-
Contact Us
- (888) 463-6332
- (301) 796-3400
- druginfo@fda.hhs.gov
Division of Drug Information (CDER)
Office of Training and Communication
WO51-2201
10903 New Hampshire Avenue
Silver Spring, MD 20993
-
-
-